The annual festival of medical research, to promote dialogue with the public about the global benefits of MRCG’s scientific research was recently held at the Fajara site.

BAIS students aged 14-15 years old and their teachers visited The MRC Unit The Gambia Field Station in Keneba recently, to see practical aspects of what they learned in their basic science class in

A study recently published by Dr Alansana Darboe, Senior Scientific Officer, from the Nutrition Theme of MRC Unit The Gambia, demonstrate that the activity of 'Natural Killer (NK) Cells, which

Dr Mohammed is committed to contributing more towards the bioinformatics work in The UnitDr Nuredin Mohammed joined MRCG as a Biostatistician in August 2016.

MRC Unit The Gambia will be holding an open day at Serekunda General Hospital on Thursday 29th June 2017.

Mr Jacob Otu Higher Scientific Officer on the WANETAM project Mr Jacob Otu was the Higher Scientific Officer on the West African Node of Excellence for Tuberculosis (TB), AIDS and Malaria (WANETAM)

The Open day of the Pneumococcal Conjugate Vaccine (PCV10) and the PregnAnZI-2 trials was an exciting opportunity to interact with the local community to learn exciting new interventions for improv

The Director of the NIH National Institute of Allergy and Infectious Diseases (NIAID) Office in Mali, Dr Fatoumata Bathily and Souleymane Karambe, Senior Support Services Supervisor, visited MRCG f

WHO Global Hepatitis report describes, for the first time, the global and regional estimates on viral hepatitis in 2015, setting the baseline for tracking progress in implementing the new global st

MRC Unit The Gambia is hosting a workshop on the 15th June 2017 at the Bray Lecture Theatre, in Fajara.

Dr Mustapha Bittaye is a Consultant Obstetrician and Gynaecologist currently working with the Vaccines and Immunity Theme on the Protecting From Pneumococcus in Early Life (PROPEL) clinical trial.<

Amadou is a Trainee Scientific Officer working with the Vaccines and Immunity Theme on the Protecting From Pneumococcus in Early Life (PROPEL) Trial, which seeks to assess the safety and immunogeni